Regulatory News:
Medivir AB (STO:MVIR) announces that the global fourth quarter net sales of OLYSIO® (simeprevir) amounted to 321 MUSD, of which 256 MUSD were sales in the USA.
Medivir’s royalties based on sales for the fourth quarter are calculated from the highest royalty tier and currency conversion from USD to Euro is based on the YTD exchange rate. The royalty amounted to 220 MSEK (23.1 MEUR).
Help employers find you! Check out all the jobs and post your resume.
